Skip to content

Exploration of the Relationship Between the Tumor Immune Microenvironment and Prognosis in Thyroid Cancer Patients

Exploration of the Relationship Between the Tumor Immune Microenvironment and Prognosis in Thyroid Cancer Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110229
Enrollment
Unknown
Registered
2025-10-10
Start date
2025-10-10
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Prospective Study on Papillary Thyroid Carcinoma (PTC):No treatment intervention is performed.
Retrospective Study on Papillary Thyroid Carcinoma(PTC) :No treatment intervention is performed.
Retrospective Study on Follicular Thyroid Carcinoma (FTC):No treatment intervention is performed.
Retrospective Study on Medullary Thyroid Carcinoma (MTC):No treatment intervention is performed.
Retrospective Study on Anaplastic Thyroid Carcinoma (ATC):No treatment intervention is performed.
Prospective Study on Follicular Thyroid Carcinoma (FTC):No treatment intervention is performed.
Prospective Study on Medullary Thyroid Carcinoma (MTC):No treatment intervention is performed.
Prospective Study on Anaplastic Thyroid Carcinoma (ATC):No treatment intervention is performed.

Sponsors

Southern Medical University Nanfang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Voluntarily sign the informed consent form; 2.Aged 18 years or older (including 18 years old); 3.Gender: Both males and females are eligible; 4.Pathologically diagnosed with thyroid tumor; 5.ECOG performance status score: 0–4 points.

Exclusion criteria

Exclusion criteria: 1.Patients with other infections 2.Patients with other underlying diseases that affect immunity 3.Patients deemed unsuitable for participation in this study by the researcher(s)

Design outcomes

Primary

MeasureTime frame
Complete Blood Count;Liver Function Tests;Renal Function Tests;Infection Markers;Six Ion Tests;Five Coagulation Tests;Thyroid Function;Serum Thyroid-Associated Antibodies;Tumor Markers;

Countries

China

Contacts

Public ContactWeisheng Chen

Nanfang Hospital, Southern Medical University

chenws_smu@163.com+86 156 2517 4481

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026